[HTML][HTML] Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
Background Lung squamous cell carcinoma (LUSC) accounts for 20–30% of non-small cell
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
[PDF][PDF] Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
M Choi, H Kadara, J Zhang, ER Parra… - Annals of …, 2017 - researchgate.net
Background: Lung squamous cell carcinoma (LUSC) accounts for 20–30% of non-small cell
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
[HTML][HTML] Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
M Choi, H Kadara, J Zhang, ER Parra… - Annals of …, 2017 - annalsofoncology.org
Background Lung squamous cell carcinoma (LUSC) accounts for 20–30% of non-small cell
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
M Choi, H Kadara, J Zhang, ER Parra… - Annals of Oncology …, 2017 - europepmc.org
Background Lung squamous cell carcinoma (LUSC) accounts for 20–30% of non-small cell
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
[HTML][HTML] Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
M Choi, H Kadara, J Zhang, ER Parra… - Annals of …, 2017 - ncbi.nlm.nih.gov
Background Lung squamous cell carcinoma (LUSC) accounts for 20–30% of non-small cell
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
[引用][C] Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
M Choi, H Kadara, J Zhang, ER Parra… - Annals of …, 2017 - cir.nii.ac.jp
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and
correlation with markers of immune function | CiNii Research CiNii 国立情報学研究所 学術 …
correlation with markers of immune function | CiNii Research CiNii 国立情報学研究所 学術 …
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
M Choi, H Kadara, J Zhang… - Annals of …, 2017 - mdanderson.elsevierpure.com
Background: Lung squamous cell carcinoma (LUSC) accounts for 20-30% of non-small cell
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
M Choi, H Kadara, J Zhang, ER Parra… - Annals of …, 2017 - snucm.elsevierpure.com
Background: Lung squamous cell carcinoma (LUSC) accounts for 20-30% of non-small cell
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
M Choi, H Kadara, J Zhang… - Annals of oncology …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Lung squamous cell carcinoma (LUSC) accounts for 20–30% of non-small cell
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
M Choi, H Kadara, J Zhang, ER Parra… - Annals of Oncology …, 2017 - europepmc.org
Background Lung squamous cell carcinoma (LUSC) accounts for 20–30% of non-small cell
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …
lung cancers (NSCLCs). There are limited treatment strategies for LUSC in part due to our …